April 28, 2025 01:20 PM EDT
China
Pharma
Manufacturing

WuXi AppTec sees growth af­ter 2024 dip, plans ‘lean’ op­er­a­tions to tem­per ‘ex­ter­nal op­por­tu­ni­ties’

Anna Brown

News Reporter

WuXi AppTec’s rev­enue rose for the first few months of 2025, sig­nal­ing that pres­sures from the pro­posed Biose­cure Act may be sub­sid­ing even as the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Bio­haven gets an up to $600M in­vest­ment; Prile­nia, Fer­rer make a deal in Eu­rope

Rev­o­lu­tion Med­i­ci­nes' KRAS drug shows po­ten­tial in ear­ly cut of lung can­cer da­ta

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times